Table 2.
Change in Renal Parameters with Treatment in All Subjects †
| suPAR, pg/mL* | Median Pre (IQR) | Median Post (IQR) | P-value |
|---|---|---|---|
| Overall (n=7) | 6781 (5821 – 8557) | 4129 (3270 – 5949) | 0.02 |
| PXP alone (n=1) | 5821 | 3173 | na |
| PXP + Rituximab (n=6) | 7264 (6022 – 11416) | 4223 (3592 – 5949) | 0.03 |
| Foot Process Effacement, % | Mean Pre ± SD | Mean Post ± SD | P-value |
| Overall (n=16) | 57 ± 33 | 22 ± 22 | 0.0001 |
| PXP alone (n=6) | 76 ± 31 | 37 ± 29 | 0.01 |
| PXP + Rituximab (n=9) | 42 ± 30 | 14 ± 11 | 0.01 |
| Serum Creatinine, mg/dL | Median Pre (IQR) | Median Post (IQR) | P-value |
| Overall (n=24) | 2.3 (1.7 – 3.3) | 1.9 (1.5 – 2.3) | 0.08 |
| PXP alone (n=12) | 2.2 (1.9 – 4.2) | 1.8 (1.6 – 2.2) | 0.33 |
| PXP + Rituximab (n=12) | 2.3 (1.5 – 3.0) | 1.9 (1.3 – 3.0) | 0.25 |
| eGFR, mL/min per 1.73 m2 | Median Pre (IQR) | Median Post (IQR) | P-value |
| Overall (n=24) | 32.9 (20.6 – 44.2) | 39.3 (28.8 – 63.4) | <0.0001 |
| PXP alone (n=12) | 33.7 (17.5 – 43.4) | 42.4 (31.7 – 63.4) | 0.33 |
| PXP + Rituximab (n=12) | 32.9 (24.1 – 49.2) | 36.3 (27.1 – 65.5) | 0.14 |
| Proteinuria, g/g | Mean Pre ± SD | Mean Post ± SD | P-value |
| Overall (n=21) | 5.1 ± 3.8 | 2.1 ± 2.8 | 0.003 |
| PXP alone (n=10) | 4.3 ± 4.1 | 2.0 ± 3.5 | 0.15 |
| PXP + Rituximab (n=10) | 5.8 ± 3.8 | 2.3 ± 2.2 | 0.01 |
| Mean Peak ± SD | Mean Post ± SD | P-value | |
| Overall (n=22) | 11.0 ± 11.4 | 4.7 ± 10.2 | 0.0001 |
| PXP alone (n=9) | 4.5 ± 4.3 | 2.0 ± 3.8 | 0.17 |
| PXP + Rituximab (n=12) | 12.2 ± 13.3 | 6.8 ± 13.3 | 0.0002 |
SD, standard deviation; PXP, plasmapheresis, eGFR: estimated glomerular filtration rate.
†
Overall results include data from one subject who only received intensification of immunosuppression but not plasmapheresis or rituximab for FSGS treatment.
*
Excludes individuals who underwent ABO-incompatible renal transplantation